IDH2 and acute myeloid leukemia: The complex biology of resistance was also highlighted in AML treated with ivosidenib (an inhibitor of mutated IDH1), whereby the concurrence of different mechanisms, particularly receptor tyrosine kinase pathway mutations and IDH-related mutations, contributed to primary and secondary resistance [47].